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j ourna l homepage: www.e lsev ie r .com/ locate /atgEditorialEditorialThis issue contains several regular articles alongwith a featured spe-
cial section on lifestyle genetics. Written by researchers and experts
from around theworld, the breadth of topics covered reﬂects bothmul-
tidisciplinary and global contributions to advancing applied and transla-
tional genomics, as deﬁned in previous issues.
The regular articles cover original research, a case report, and topical
issues in big data, reimbursement, and education. The research article
and case report contribute to the scientiﬁc need for genomics to be
more globally diverse, particularly in low resourced nations. In ‘NGS
Meta Data Analysis for Identiﬁcation of SNPs and INDELs Pattern in
Human AirwayTranscriptome: A Preliminary Indicator for Lung Cancer’,
Dr. Sathya et al. report preliminary results of SNPs and INDEL discovery
in the human airway transcriptome of individuals with and without
lung cancer and who are or aren't smokers in efforts to identify SNP
and INDEL patterns responsible for lung cancer in India. Lung cancer in-
cidence is on the rise in India. Recent research estimates that 87% of
males and 85% of females with lung cancer have a history of active to-
bacco smoking. Passive tobacco exposure has been linked to 3% of all
cases and a recent meta-analysis of 41 studies showed that the risk of
developing lung cancer increases with increased exposure.1 Using
next generation sequencing, the authors found 5 SNPs and 2 INDELs in
the SCGB1A1, SCGB3A1 and NKFB1A genes of smokers, suggesting a
signature for disease pathogenesis. Findings are preliminary, requiring
more analysis and wet lab validation, yet they provide a resource for
further genetic studies of smokers and the development of precision
medicine.
Dr. Ben Brahim reports a unique case of Beckwith–Wiedemann
Syndrome (BWS) in Tunisia. She reports on a novel form BWS, in
‘Partial KCNQ1OT1 Hypomethylation: a Disguised Familial Beckwith
Wiedemann Syndrome as a Sporadic Adrenocortical Tumor’. Molecular
analysis of an infant presentingwith an adrenocortical tumor, and a fam-
ily history of such tumors, revealed partial KCNQ1OT1 hypomethylation
and complete loss of methylation in the adrenocortical tumor. Incom-
plete penetrance and speciﬁc tissue mosasicism are thought to explain
the new presentation.
This issue's news & views report proceedings of an expert panel
discussion on big data challenges and key strategic needs in precision
medicine, held at the 6th annual Personalized Medicine Partnership
meeting, Arrowhead Publishers, 2014. Translational bioinformaticians
representing a broad range of expertise delivered an informative and
lively presentation. Experts deﬁned the problem, identiﬁed speciﬁc
unmet needs and emerging trends in knowledge generation methods
and analyzed consent restrictions. While important shifts to cloud
storage, open collaborative platforms and integrated approaches1 Behera, D., Lung Cancer in India. Medicine Update 2012 vol. 22, 401–7.
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medicine's challenge to solve.
Dr. Hafez's commentary ‘Precision Medicine is Here, Break Out Your
Wallet’ challenges the notion that precision medicine is really here,
based on the economic realities of the U.S.'s health care system. When
technological feats such as the $1000 genome are pitted against earning
reports of large publically traded companies offering genetic testing and
signiﬁcant ﬁnancial losses and reduced Medicare reimbursements,
Hafez argues, it is readily evident that payer and clinical adoption of ge-
netic testing is lagging behind technological capabilities. He explains
why major reimbursement policy is needed if precision medicine is to
attain its promised goals.
Clinical adoption of genomic advances is constrained not only by re-
imbursement issues but also by family physicians' lack of sufﬁcient
knowledge and skill, particularly in regard to handling emerging ethical
issues. Zawati et al. present a pilot study designed to address these
unmet educational needs through a comprehensive multi-pronged
training strategy. ‘Ethics Education for Clinician-Researchers in Genetics:
The Combined Approach discusses the development, implementation
and learning satisfaction of the conference delivering the novel approach.
They recommend adoption by medical schools, clinics and hospitals and
results of such programs will be instructive.Lifestyle genomics
Advances in epigenetics and understandings of the dynamic rela-
tionship between genotype and phenotype have led to increasing re-
search interest in overlaps between lifestyle and genomics. An upshot
is that once disparate domains of research, lifestyle and genomics, are
now working together to unravel mysteries.
The purpose of this special section is to present this initiative and
current research in various countries.
The article by Lucivero and Prainsack, discusses how direct-to-
consumer testing is typically used. Although laws in the different coun-
tries vary in limitations imposed on companies sellingDTC kits, a person
can often buy kits and take a test, e.g. swab the inside of their cheek or
spit saliva into a cup, in the privacy of their home and soon thereafter
learn if they are likely to be affected by cancer, or some other afﬂiction,
in the coming years. Regulators and ethicists have questioned whether
DTC tests are appropriate since they hit the market more than a decade
ago. The authors analyze frequently raised issues such as concern about
the use of a test not clinically validated, or the reporting of a wrong re-
sult. What is the ethical impact of all this? Should governments protect
users from harm? Should individuals have the right to take such tests in
the name of genetic tourism or genetic recreation?
Nutrigenomics, often referred to as nutritional genomics, is the in-
vestigation of the relationship of diet and genes to health and disease.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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discipline that examines the association of gene variants (SNPs) with
intermediate risk factors, such as glucose response.2 Commercial
nutrigenomic tests have promised people a scientiﬁc way to choose a
diet that optimizes their health. However, the science supporting the
test and its result is often lacking, as Pavlidis et. al. discuss. They explain
the scientiﬁc complexities and why commercial promises of optimal
health through a scientiﬁcally proven optimal diet are illusory. Further,
they discuss the fact that despite scientiﬁc advances in nutrigenomics,
there is not a deﬁnite scientiﬁcally supported way of applying research
ﬁndings. In analyzing the clinical and commercial impact of the ﬁeld,
they point to research ‘gaps’ and identify what current literature says
and importantly doesn't say.
How an individual's genes inﬂuence their athletic ability, the ge-
nomics of exercise, is another budding ﬁeld in lifestyle genetics.
Among questions currently researched is how do systems as renin-
angiotensin inﬂuence the way that the genes and certain genotypes
respond to them? The article by Van Gingel et al. investigates the way
that the renin-angiotensin system could be inﬂuenced during exercise
in the ACE I/D gene polymorphism, suggesting that genes play impor-
tant roles in regulatory systems.
Arguably, one of the overarching goals of lifestyle genetics is to
determine how to maximize health for the longest period of time.
Research on the genetics of longevity has been underway at several
institutions for at least a decade. Govindaraju et al. provide a thorough
analysis of how longevity is inﬂuenced by genetic and epigenetic2 http://nutrigenomics.ucdavis.edu/?page=information/Glossary.factors. This article shows the need for more research to be made in
order to know more on the mechanisms inﬂuencing human longevity.
Finally, the implementation of DTC tests as well as the utility of
ﬁndings raises a host of ethical issues. The returning of ﬁndings, partic-
ularly incidental ﬁndings, is controversial and highly debated. Lucivero
and Prainsack offer an interesting perspective on these issues in their
discussion of the ‘lifestylization’ of health. In concert, they, Clift et al.
and Pavlidis et al., discuss ethical complexities of result returning, in-
cluding incidental ﬁndings, in different clinical contexts and to different
types of patients.Which results ought a health professional return to the
patients, or which patients? Given that not all patients are equally
prepared to receive results regarding life-threatening conditions, what
type of clinical standard ought to exist? Can professionals truly antici-
pate how patients and their relatives will be affected by incidental
results? How ought clinicians handle these complexities?
In sum, this issue illustrates that genomic progress generates
answers but also questions. Deciding whether we know enough to
apply what we know is understandably challenging. Medicine, as
William Osler so famously said, is a science of uncertainty.3
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